Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Idenix Pharmaceuticals LLC et al v. Gilead Sciences, Inc.
Case Number:
1:14-cv-00846
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 16, 2018
Merck Unit Loses $2.5B Verdict As Hep C Patent Invalidated
A Delaware federal judge dismantled a Merck & Co. unit's $2.5 billion jury verdict win over Gilead Sciences Inc. in an infringement suit over a hepatitis C drug patent, finding Friday that the patent's claims weren't specific enough for an experienced scientist to successfully re-create the formula.
-
September 22, 2017
Merck's Idenix Denied Enhanced Damages On $2.5B Verdict
A Delaware federal judge denied enhanced damages Friday to Merck & Co. unit Idenix after its $2.5 billion win over Gilead Sciences Inc. in a jury trial claiming infringement of a patent behind two blockbuster hepatitis C medicines, saying both the judge's own pretrial decisions and the jury's findings were "close."